Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE561.85-8.1 (-1.42 % )
PREV CLOSE (Rs.) 569.95
OPEN PRICE (Rs.) 568.25
BID PRICE (QTY) 562.20 (77 )
OFFER PRICE (QTY) 562.45 (148 )
VOLUME 66341
TODAY'S LOW / HIGH (Rs.)557.60 575.35
52 WK LOW / HIGH (Rs.)562.15 838
NSE560.95 -8.95 (-1.57 % )
PREV CLOSE(Rs.) 569.90
OPEN PRICE (Rs.) 574.00
BID PRICE (QTY) 560.60 (229 )
OFFER PRICE (QTY) 560.95 (2022 )
VOLUME 946264
TODAY'S LOW / HIGH(Rs.) 557.10 575.65
52 WK LOW / HIGH (Rs.)562.1 838

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.44
TTM EPS (Rs.) 26.11
P/E Ratio 21.53
Book Value (Rs.) 193.72
Face Value (Rs.) 1
MCap (Rs. in Mn) 329284.57
Price/Earning (TTM) 16.95
Price/Sales (TTM) 2.76
Price/Book (MRQ) 2.90
PAT Margin (%) 17.59
ROCE (%) 19.02
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
11Jul07-11-2019$Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets Aurobindo Pharma launches Ci

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets..
11Jul07-11-2019$Aurobindo Pharma advances on launching Cinacalcet Hydrochloride Tablets Aurobindo Pharma advances on

Aurobindo Pharma is currently trading at Rs. 605.00, up by 7.60 points or 1.27% from its previous closing of Rs. 597.40 on the BSE.

The scrip opened at Rs. 603.10 and has touched a high and low of Rs. 621.70 and Rs. 599.60 respectively. So far 211876 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.

Last one week high and low of the scrip stood at Rs. 621.70 and Rs. 582.35 respectively. The current market cap of the company is Rs. 35447.89 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 605.00, up by 7.60..
11Jul07-11-2019$KPI Global Infrastructure, Religare Enterprises and Aurobindo Pharma to see some action today KPI Global Infrastructure, R

KPI Global Infrastructure has signed Power Purchase Agreement (PPA) with Super Deluxe Paper Mills, Vapi for sale of 1 MW solar power for a period of 15 years under the category of Independent Power Producer (IPP).

Religare Enterprises has entered into a binding term sheet with TCG Advisory Services, Religare Finvest (RFL) and Religare Housing Development Finance Corporation (RHDFCL), whereby the company will divest its entire stake in RFL, a subsidiary of the Company, to TCG Advisory Services or any of its affiliates.

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Premier Explosives has bagged an order from Bharat Dynamics (BDL) for supply of solid propellants for Medium Range Surface to Air Missile (MRSAM) for a value of Rs 14.99 crore (including GST) to be executed within a period of 14 months.

Trident has reported 11,702 metric tons production of Paper in June 2019. Further, chemicals production stood at 7,528 metric tons. The company’s bath linen and yarn production stood at 4,023 metric tons and 9,133 metric tons, respectively, while bed linen production stood at 1.75 million metres during June.

Bharti Airtel has partnered with Irish and India based global EdTech, Shaw Academy to offer popular online courses to its mobile customers, as part of the fast expanding range of exciting benefits under its refreshed ‘AirtelThanks program’. As part of their exclusive AirtelThanks benefits, Airtel Platinum mobile customers will now get a one year access to the entire Shaw Academy course library worth Rs 6000.

Datamatics Global Services has collaborated with Thomson Reuters to bring together TaxAnalyze, a Tax Validation tool. The product will help corporates streamline their financial information, automate tax processes and ensure seamless tax calculations. The solution is powered by Thomson Reuters ONESOURCE and Datamatics TruBI.

KPI Global Infrastructure has signed Power Purchase Agreement (..
04Jul07-04-2019$USFDA pulls up Aurobindo Pharma for 'repeated' failures in CGMP USFDA pulls up Aurobindo Pha

The US Food and Drug Administration (USFDA) has pulled up Aurobindo Pharma for 'repeated' violations in current good manufacturing practice (CGMP) at three of its plants in manufacturing certain active pharmaceutical ingredients (API) and intermediates. The repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate.

The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API. Aurobindo unit I and Aurobindo unit IX were also inspected and cited for CGMP deficiencies related to the manufacture of (b)(4) API and intermediates.  These facilities were also considered to be in an unacceptable state of compliance with regards to CGMP.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

The US Food and Drug Administration (USFDA) has pulled up Aurob..
04Jul07-04-2019$Aurobindo Pharma trades higher on the BSE Aurobindo Pharma trades high

Aurobindo Pharma is currently trading at Rs. 603.80, up by 7.70 points or 1.29% from its previous closing of Rs. 596.10 on the BSE.

The scrip opened at Rs. 595.50 and has touched a high and low of Rs. 604.60 and Rs. 593.60 respectively. So far 59322 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.

Last one week high and low of the scrip stood at Rs. 625.65 and Rs. 588.00 respectively. The current market cap of the company is Rs. 35398.09 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.

The US Food and Drug Administration (USFDA) has pulled up Aurobindo Pharma for 'repeated' violations in current good manufacturing practice (CGMP) at three of its plants in manufacturing certain active pharmaceutical ingredients (API) and intermediates. The repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate.

The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API. Aurobindo unit I and Aurobindo unit IX were also inspected and cited for CGMP deficiencies related to the manufacture of (b)(4) API and intermediates.  These facilities were also considered to be in an unacceptable state of compliance with regards to CGMP.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 603.80, up by 7.70..
Financials More
Rs. in Millions
QTR Mar 19 ANNUAL 19
Net Profit4601.415297.3
Gross Profit 6184.8 19646.2
Operating Profit 7626.525085.7
Net Sales 32805.8122578.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Fredun Pharma (BSE)
 405.00 (3.89%)
M.Cap ( in Cr)
161.58
Sanofi India (BSE)
 5923.70 (0.17%)
M.Cap ( in Cr)
13806.86
Ipca Laboratories (BSE)
 942.35 (1.01%)
M.Cap ( in Cr)
11712.84
Everest Organics (BSE)
 157.60 (5.07%)
M.Cap ( in Cr)
126.08
Natco Pharma (BSE)
 511.00 (0.91%)
M.Cap ( in Cr)
9293.50
Shareholding Pattern More
PROMOTERS 51.87 %
MUTUAL FUNDS/UTI 13.45 %
NON-INSTITUTION 12.97 %
FI/BANKS/INSURANCE 0.24 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes